caa a22 4500 445796480 CHVBK 20180317145127.0 cr unu---uuuuu 170323e20110801xx s 000 0 eng 10.1007/s10620-011-1765-0 doi (NATIONALLICENCE)springer-10.1007/s10620-011-1765-0 Peginterferon Alfa-2a Is Superior to Peginterferon Alfa-2b in the Treatment of Naïve Patients with Hepatitis C Virus Infection: Meta-Analysis of Randomized Controlled Trials [Elektronische Daten] [Ashwani Singal, Sarat Jampana, Bhupinderjit Anand] Background: Pegylated interferon (PEGIFN) and ribavirin combination is the standard of care for the treatment of chronic hepatitis C virus (HCV) infection. Studies comparing the efficacy and safety of PEGIFN alfa-2a and PEGIFN alfa-2b in treatment-naïve HCV-infected patients have shown conflicting results. Aim: We performed a systematic review and meta-analysis of studies comparing the efficacy and safety of PEGIFN alfa-2a and PEGIFN alfa-2b in HCV-infected patients naïve to treatment. Methods: Nine studies (five abstracts) with 3,546 patients (1,771 treated with PEGIFN alfa-2a) comparing PEGIFN alfa-2a and PEGIFN alfa-2b in treatment-naïve HCV patients were analyzed. Efficacy outcomes were sustained virologic response (SVR) and treatment discontinuation rates due to serious adverse effects (SAE). Results: Pooled data on outcomes (reported as odds ratios [ORs] with 95% confidence intervals [CIs]: [OR (95% CI)]) showed higher SVR in patients treated with PEGIFN alfa-2a as compared to treatment with PEGIFN alfa-2b [1.36 (1.07-1.73); P=0.01]. Subgroup analysis of good quality studies on SVR in genotypes 2 and 3 also favored PEGIFN alfa-2a over PEGIFN alfa-2b (1.91 [1.09-3.37]; P=0.02). SVR results obtained with the two types of IFN showed no impact of viral load and the presence or absence of cirrhosis. Treatment discontinuation rates due to SAE, reported in six studies (two abstracts) on 3,211 patients (1,604 treated with PEGIFN alfa-2a), were similar in the two types of PEGIFN [0.66 (0.37-1.16); P=0.15]. Conclusions: PEGIFN alfa-2a has superior efficacy with higher SVR as compared to PEGIFN alfa-2b in treatment-naïve HCV-infected patients. The safety profile of the two types of PEGIFN was similar. Springer Science+Business Media, LLC, 2011 Hepatitis C virus nationallicence HCV nationallicence Pegylated interferon alfa-2a nationallicence Pegylated interferon alfa-2b nationallicence Antiviral therapy nationallicence Meta-analysis nationallicence Singal Ashwani Department of Internal Medicine, University of Texas Medical Branch, 77555-0764, Galveston, TX, USA aut Jampana Sarat Department of Internal Medicine, University of Texas Medical Branch, 77555-0764, Galveston, TX, USA aut Anand Bhupinderjit Department of Gastroenterology and Hepatology, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, TX, USA aut Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/8(2011-08-01), 2221-2226 0163-2116 56:8<2221 2011 56 10620 https://doi.org/10.1007/s10620-011-1765-0 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10620-011-1765-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Singal Ashwani Department of Internal Medicine, University of Texas Medical Branch, 77555-0764, Galveston, TX, USA aut NATIONALLICENCE 700 1- Jampana Sarat Department of Internal Medicine, University of Texas Medical Branch, 77555-0764, Galveston, TX, USA aut NATIONALLICENCE 700 1- Anand Bhupinderjit Department of Gastroenterology and Hepatology, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, TX, USA aut NATIONALLICENCE 773 0- Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/8(2011-08-01), 2221-2226 0163-2116 56:8<2221 2011 56 10620 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer